#USA #London #Clinical Trials #Image Analysis Group #DYNAMIKA V.7

Image Analysis Group Launches DYNAMIKA V.7

The Image Analysis Group (IAG), a prominent player in the imaging Clinical Research Organization (iCRO) sector, has officially announced the launch of its cutting-edge platform, DYNAMIKA V.7. This advanced cloud-based system is designed specifically for the management and analysis of imaging data in clinical trials, and it has quickly garnered attention for its innovative features and compliance with stringent standards.

Recently, DYNAMIKA V.7 achieved the British Standards Institute (BSI) surveillance audit certification, following the successful completion of a SOC II Type I compliance certification. These milestones reinforce IAG's commitment to quality and regulatory adherence as the company strives to provide reliable imaging solutions for clinical research.

In 2024, DYNAMIKA was honored as an Award Category Winner for Innovation at the Pharmaceutical Technology Excellence Awards. This recognition highlights the platform's proprietary technology and its transformative potential within the pharmaceutical sector. Dr. Olga Kubassova, the founder and President of IAG, expressed her enthusiasm for this achievement, stating, "This milestone is another important step as IAG continues to bring innovation to the medical imaging space. With comprehensive quality compliance, we can collaborate more effectively with companies aiming to leverage imaging biomarkers to support the safety and efficacy of their drug candidates in clinical trials."

DYNAMIKA V.7 simplifies the medical imaging workflow, streamlining processes and enhancing data management in clinical trials through its user-friendly interface. The platform's sophisticated features include:

• - Automated Imaging Workflows: The automation of imaging workflows reduces administrative burdens, allowing clinical sites to focus on patient care and trial participation.
• - Accelerated Radiological Readings: DYNAMIKA improves the efficiency of the radiological reading process, thus enhancing site collaboration and participation in clinical trials.
• - Enhanced Consistency: By promoting uniformity in radiological interpretations, DYNAMIKA increases the accuracy and dependability of imaging assessments.
• - Data Interoperability: The platform consolidates data from various sources, providing operational leaders with real-time insights necessary for informed decision-making.
• - Support for Various Phase Trials: DYNAMIKA is versatile, accommodating Phase I-IV trials of all sizes, making it a valuable asset for clinical researchers.

The development of DYNAMIKA V.7 adheres to 21 CFR Part 11, which governs FDA regulations regarding electronic records and signatures. Additionally, it aligns with ISO 13485, the globally recognized standard for quality management systems in medical device design and manufacture. These compliance initiatives underline IAG’s dedication to maintaining the highest standards of quality, security, and compliance within clinical research.

Since its inception in 2007, IAG has been a trusted partner for biotech and pharmaceutical companies globally, proficiently managing all aspects of imaging trials across numerous indications. The launch of DYNAMIKA V.7 is a testament to the company's ongoing commitment to pushing the boundaries of innovation in clinical research, ultimately enhancing the value and market potential of novel therapeutic assets.

For further insights or inquiries about DYNAMIKA V.7, you can contact Brittany Kearns at IAG via phone at 571-271-7211 or email her at [email protected]. IAG continues to lead in the domain of imaging clinical trials, with this newest platform poised to redefine engagement and effectiveness in medical research efforts.